157 related articles for article (PubMed ID: 37197964)
1. An Iron-chelating Agent Improved the Cardiac Function in a Patient with Severe Heart Failure Due to Hereditary Hemochromatosis.
Setoguchi A; Kawano H; Okano S; Honda T; Kato T; Dateki S; Senoo A; Nakashima Y; Motokawa T; Ueno Y; Akashi R; Yonekura T; Sueyoshi E; Ikeda S; Miyazaki Y; Maemura K
Intern Med; 2024 Jan; 63(2):253-258. PubMed ID: 37197964
[TBL] [Abstract][Full Text] [Related]
2. Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report.
Cooray SD; Heerasing NM; Selkrig LA; Subramaniam VN; Hamblin PS; McDonald CJ; McLean CA; McNamara E; Leet AS; Roberts SK
J Med Case Rep; 2018 Jan; 12(1):18. PubMed ID: 29373985
[TBL] [Abstract][Full Text] [Related]
3. Fatal Cardiac Hemochromatosis in a Patient with Hereditary Spherocytosis.
Fujino T; Inoue S; Katsuki S; Higo T; Ide T; Oda Y; Tsutsui H
Int Heart J; 2018 Mar; 59(2):427-430. PubMed ID: 29563373
[TBL] [Abstract][Full Text] [Related]
4. Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone.
Tauchenová L; Křížová B; Kubánek M; Fraňková S; Melenovský V; Tintěra J; Kautznerová D; Malušková J; Jirsa M; Kautzner J
Can J Cardiol; 2016 Dec; 32(12):1574.e1-1574.e3. PubMed ID: 27789107
[TBL] [Abstract][Full Text] [Related]
5. Severe Myocardial Dysfunction Reversed by Iron-Chelation Therapy in an Asian Patient with Hereditary Hemochromatosis.
Kang Y; Chen XJ; Yu CP; You GY; Zhang Q
Am J Med Sci; 2016 May; 351(5):546-8. PubMed ID: 27140717
[No Abstract] [Full Text] [Related]
6. Cardiac involvement in hemochromatosis.
Gulati V; Harikrishnan P; Palaniswamy C; Aronow WS; Jain D; Frishman WH
Cardiol Rev; 2014; 22(2):56-68. PubMed ID: 24503941
[TBL] [Abstract][Full Text] [Related]
7. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH).
Fabio G; Minonzio F; Delbini P; Bianchi A; Cappellini MD
Blood; 2007 Jan; 109(1):362-4. PubMed ID: 16960153
[TBL] [Abstract][Full Text] [Related]
8. Histological changes in cardiac hemochromatosis improved by an iron-chelating agent. A biopsy case.
Tashiro A; Satodate R; Segawa I
Acta Pathol Jpn; 1990 Apr; 40(4):288-92. PubMed ID: 2371834
[TBL] [Abstract][Full Text] [Related]
9. Haemochromatosis presenting as congestive cardiac failure.
Porter J; Cary N; Schofield P
Br Heart J; 1995 Jan; 73(1):73-5. PubMed ID: 7888267
[TBL] [Abstract][Full Text] [Related]
10. [Heart failure in hemochromatosis. Apropos of a case].
Marty C; Elghozi D; Kulas A; Reboul M; Lainée J; Aubert P
Ann Med Interne (Paris); 1973; 124(6):507-11. PubMed ID: 4270967
[No Abstract] [Full Text] [Related]
11. Progressive hemochromatotic cardiomyopathy despite reversal of iron deposition after liver transplantation.
Westra WH; Hruban RH; Baughman KL; Olson JL; Porterfield JK; Mitchell MC; Hutchins GM
Am J Clin Pathol; 1993 Jan; 99(1):39-44. PubMed ID: 8422014
[TBL] [Abstract][Full Text] [Related]
12. Reversible cardiomyopathy in a patient with juvenile hemochromatosis.
Blank R; Wolber T; Maeder M; Rickli H
Int J Cardiol; 2006 Jul; 111(1):161-2. PubMed ID: 15992946
[No Abstract] [Full Text] [Related]
13. Cardiac iron overload following liver transplantation in patients without hereditary hemochromatosis or severe hepatic iron deposition.
Papadodima S; Masia R; Stone JR
Cardiovasc Pathol; 2019; 40():7-11. PubMed ID: 30763826
[TBL] [Abstract][Full Text] [Related]
14. Advances in the use of iron-chelating agents for the treatment of iron overload.
Modell B
Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
[No Abstract] [Full Text] [Related]
15. Endomyocardial biopsy in hemochromatosis: clinicopathologic correlates in six cases.
Olson LJ; Edwards WD; Holmes DR; Miller FA; Nordstrom LA; Baldus WP
J Am Coll Cardiol; 1989 Jan; 13(1):116-20. PubMed ID: 2909558
[TBL] [Abstract][Full Text] [Related]
16. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis.
Park SJ; Han CW
J Korean Med Sci; 2008 Apr; 23(2):320-3. PubMed ID: 18437019
[TBL] [Abstract][Full Text] [Related]
17. [Adiastole caused by a secondary cardiac hemochromatosis. Successful treatment with an iron chelating agent].
Baudouy P; Lombrail P; Azancot I; Piekarski A; Martin E; Slama R
Arch Mal Coeur Vaiss; 1983 Oct; 76(10):1240-6. PubMed ID: 6418103
[TBL] [Abstract][Full Text] [Related]
18. [Juvenile haemochromatosis presenting as intractable congestive heart failure].
Vas K; Hubay M; Tordai A; Andrikovics H; Zoltán S; Jánosi A
Orv Hetil; 2005 Dec; 146(51):2605-8. PubMed ID: 16468615
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.
Cançado R; Melo MR; de Moraes Bastos R; Santos PC; Guerra-Shinohara EM; Chiattone C; Ballas SK
Eur J Haematol; 2015 Dec; 95(6):545-50. PubMed ID: 25684349
[TBL] [Abstract][Full Text] [Related]
20. [Intensifying iron chelating therapy with desferrioxamine using implantable venous access catheters (Port-A-Cath)].
de Montalembert M; Jan D; Clairicia M; Hannedouche T; Sidi D; Girot R
Arch Fr Pediatr; 1992 Mar; 49(3):159-63. PubMed ID: 1610270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
